PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSE PRESCRIBERS,QUESTIONS &
ANSWERS FULLY ANALYSED EDITION EXAM 100% CORRECTLY/VERIFIED ANSWERS WITH
SATISFACTION GUARANTEED SUCCESS LATEST UPDATE 2025/2026 5TH EDITION WOO ROBINSON
TEST BANK GRADED A+
Chapter 1.
An Introduction to Pharmacogenetics
Multiple Choice
Identify the choice that best completes the statement or answers the question.
1. Genetic polymorphisms account for differences in metabolism, including:
1. Poor metabolizers, who lack a working enzyme
2. Intermediate metabolizers, who have one working, wild-type allele and one mutant
3. Extensive metabolizers, with two normally functioning alleles
4. All of the above
2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
1. A need to monitor drugs metabolized by 2D6 for toxicity
2. Increased dosages needed of drugs metabolized by 2D6, such as the
selective seroto reuptake inhibitors
3. Decreased conversion of codeine to morphine by CYP 2D6
4. The need for lowered dosages of drugs, such as beta blockers
3. Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
2. Cause toxic levels of drugs, such as oral contraceptives, when coadministered
3. Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
4. Cause nonspecific changes in drug metabolism
4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
1. Decreased therapeutic levels of quinidine
2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-glycopr absorption and elimination
4. Increased levels of a coadministered drug, such as digoxin, that
requires P-glycopro absorption and elimination
5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
1. Toxic levels of warfarin building up
, 2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
4. Less risk of drug interactions with warfarin
6. Genetic testing for VCORC1 mutation to assess potential warfarin
resistance is required prior to prescribing warfarin.
1. True
2. False
7. Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
1. Erythromycin
2. Digoxin
3. Cetuximab
4. Rifampin
8. Carbamazepine has a Black Box Warning recommending testing for the
HLA-B*1502 allele in patients with Asian ancestry prior to starting
therapy due to:
1. Decreased effectiveness of carbamazepine in treating seizures in Asian patients wit
HLA-B*1502 allele
2. Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
3. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 a
4. Patients who have the HLA-B*1502 allele being more likely to
have a resistance to carbamazepine
9. A genetic variation in how the metabolite of the cancer drug
irinotecan SN-38 is inactivated by the body may lead to:
1. Decreased effectiveness of irinotecan in the treatment of cancer
2. Increased adverse drug reactions, such as neutropenia
3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
4. Increased concerns for irinotecan being carcinogenic
10. Patients who have a poor metabolism phenotype will have:
1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of pr
2. Accumulation of inactive metabolites of drugs
3. A need for increased dosages of medications
4. Increased elimination of an active drug
11. Ultra-rapid metabolizers of drugs may have:
, 1. To have dosages of drugs adjusted downward to prevent drug accumulation
2. Active drug rapidly metabolized into inactive metabolites, leading
to potential thera failure
3. Increased elimination of active, nonmetabolized drug
4. Slowed metabolism of a prodrug into an active drug, leading to an accumulation of
12. A provider may consider testing for CYP2D6 variants prior to
starting tamoxifen for breast cancer to:
1. Ensure the patient will not have increased adverse drug reactions to the tamoxifen
2. Identify potential drug-drug interactions that may occur with tamoxifen
3. Reduce the likelihood of therapeutic failure with tamoxifen treatment
4. Identify poor metabolizers of tamoxifen
Chapter 1. An Introduction to
Pharmacogenetics Answer Section
MULTIPLE CHOICE
1. ANS: 4 PTS: 1
2. ANS: 2 PTS: 1
3. ANS: 3 PTS: 1
4. ANS: 4 PTS: 1
5. ANS: 2 PTS: 1
6. ANS: 2 PTS: 1
7. ANS: 3 PTS: 1
8. ANS: 3 PTS: 1
9. ANS: 2 PTS: 1
10. 1 PTS: 1
ANS:
11. 2 PTS: 1
ANS:
12. 3 PTS: 1
ANS:
Chapter d2. dReview dof dthe dBasic dPrinciples dof dPharmacology
Multiple dChoice
, Identify dthe dchoice dthat dbest dcompletes dthe dstatement dor danswers dthe dquestion.
d dd 1. d
d dd 2. dDrugs dthat dhave da dsignificant dfirst-pass d effect:
1. Must dbe dgiven dby dthe denteral d(oral) droute donly
2. Bypass dthe dhepatic dcirculation
3. Are drapidly dmetabolized dby dthe dliver dand dmay dhave dlittle dif dany ddesired
daction
4. Are dconverted dby dthe dliver dto dmore dactive dand dfat-soluble dforms
d dd 3. dThe droute dof dexcretion dof da dvolatile ddrug dwill dlikely dbe dthe:
1.
dKidney
sd2.
d Lungs
3. Bile dand dfeces
4. Skin
d dd 4. dMedroxyprogesterone d(Depo dProvera) dis dprescribed
dintramuscularly d(IM) dto dcreate dadstorage dreservoir dof dthe ddrug.
dStorage dreservoirs:
1. Assure dthat dthe ddrug dwill dreach dits dintended dtarget dtissue
2. Are dthe dreason dfor dgiving dloading ddoses
3. Increase dthe dlength dof dtime da ddrug dis davailable dand dactive
4. Are dmost dcommon din dcollagen dtissues
d dd 5. dThe dNP dchooses dto dgive dcephalexin devery d8 dhours dbased don dknowledge dof dthe
d drug’s:
1. dPropensity dto dgo dto dthe
dtarget dreceptord2. d Biological
dhalf-life
3. Pharmacodynamics
4. Safety dand dside deffects
d dd 6. dAzithromycin ddosing drequires dthat dthe dfirst dday’s ddosage dbe dtwice dthose
ANSWERS FULLY ANALYSED EDITION EXAM 100% CORRECTLY/VERIFIED ANSWERS WITH
SATISFACTION GUARANTEED SUCCESS LATEST UPDATE 2025/2026 5TH EDITION WOO ROBINSON
TEST BANK GRADED A+
Chapter 1.
An Introduction to Pharmacogenetics
Multiple Choice
Identify the choice that best completes the statement or answers the question.
1. Genetic polymorphisms account for differences in metabolism, including:
1. Poor metabolizers, who lack a working enzyme
2. Intermediate metabolizers, who have one working, wild-type allele and one mutant
3. Extensive metabolizers, with two normally functioning alleles
4. All of the above
2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
1. A need to monitor drugs metabolized by 2D6 for toxicity
2. Increased dosages needed of drugs metabolized by 2D6, such as the
selective seroto reuptake inhibitors
3. Decreased conversion of codeine to morphine by CYP 2D6
4. The need for lowered dosages of drugs, such as beta blockers
3. Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
2. Cause toxic levels of drugs, such as oral contraceptives, when coadministered
3. Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
4. Cause nonspecific changes in drug metabolism
4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
1. Decreased therapeutic levels of quinidine
2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-glycopr absorption and elimination
4. Increased levels of a coadministered drug, such as digoxin, that
requires P-glycopro absorption and elimination
5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
1. Toxic levels of warfarin building up
, 2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
4. Less risk of drug interactions with warfarin
6. Genetic testing for VCORC1 mutation to assess potential warfarin
resistance is required prior to prescribing warfarin.
1. True
2. False
7. Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
1. Erythromycin
2. Digoxin
3. Cetuximab
4. Rifampin
8. Carbamazepine has a Black Box Warning recommending testing for the
HLA-B*1502 allele in patients with Asian ancestry prior to starting
therapy due to:
1. Decreased effectiveness of carbamazepine in treating seizures in Asian patients wit
HLA-B*1502 allele
2. Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
3. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 a
4. Patients who have the HLA-B*1502 allele being more likely to
have a resistance to carbamazepine
9. A genetic variation in how the metabolite of the cancer drug
irinotecan SN-38 is inactivated by the body may lead to:
1. Decreased effectiveness of irinotecan in the treatment of cancer
2. Increased adverse drug reactions, such as neutropenia
3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
4. Increased concerns for irinotecan being carcinogenic
10. Patients who have a poor metabolism phenotype will have:
1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of pr
2. Accumulation of inactive metabolites of drugs
3. A need for increased dosages of medications
4. Increased elimination of an active drug
11. Ultra-rapid metabolizers of drugs may have:
, 1. To have dosages of drugs adjusted downward to prevent drug accumulation
2. Active drug rapidly metabolized into inactive metabolites, leading
to potential thera failure
3. Increased elimination of active, nonmetabolized drug
4. Slowed metabolism of a prodrug into an active drug, leading to an accumulation of
12. A provider may consider testing for CYP2D6 variants prior to
starting tamoxifen for breast cancer to:
1. Ensure the patient will not have increased adverse drug reactions to the tamoxifen
2. Identify potential drug-drug interactions that may occur with tamoxifen
3. Reduce the likelihood of therapeutic failure with tamoxifen treatment
4. Identify poor metabolizers of tamoxifen
Chapter 1. An Introduction to
Pharmacogenetics Answer Section
MULTIPLE CHOICE
1. ANS: 4 PTS: 1
2. ANS: 2 PTS: 1
3. ANS: 3 PTS: 1
4. ANS: 4 PTS: 1
5. ANS: 2 PTS: 1
6. ANS: 2 PTS: 1
7. ANS: 3 PTS: 1
8. ANS: 3 PTS: 1
9. ANS: 2 PTS: 1
10. 1 PTS: 1
ANS:
11. 2 PTS: 1
ANS:
12. 3 PTS: 1
ANS:
Chapter d2. dReview dof dthe dBasic dPrinciples dof dPharmacology
Multiple dChoice
, Identify dthe dchoice dthat dbest dcompletes dthe dstatement dor danswers dthe dquestion.
d dd 1. d
d dd 2. dDrugs dthat dhave da dsignificant dfirst-pass d effect:
1. Must dbe dgiven dby dthe denteral d(oral) droute donly
2. Bypass dthe dhepatic dcirculation
3. Are drapidly dmetabolized dby dthe dliver dand dmay dhave dlittle dif dany ddesired
daction
4. Are dconverted dby dthe dliver dto dmore dactive dand dfat-soluble dforms
d dd 3. dThe droute dof dexcretion dof da dvolatile ddrug dwill dlikely dbe dthe:
1.
dKidney
sd2.
d Lungs
3. Bile dand dfeces
4. Skin
d dd 4. dMedroxyprogesterone d(Depo dProvera) dis dprescribed
dintramuscularly d(IM) dto dcreate dadstorage dreservoir dof dthe ddrug.
dStorage dreservoirs:
1. Assure dthat dthe ddrug dwill dreach dits dintended dtarget dtissue
2. Are dthe dreason dfor dgiving dloading ddoses
3. Increase dthe dlength dof dtime da ddrug dis davailable dand dactive
4. Are dmost dcommon din dcollagen dtissues
d dd 5. dThe dNP dchooses dto dgive dcephalexin devery d8 dhours dbased don dknowledge dof dthe
d drug’s:
1. dPropensity dto dgo dto dthe
dtarget dreceptord2. d Biological
dhalf-life
3. Pharmacodynamics
4. Safety dand dside deffects
d dd 6. dAzithromycin ddosing drequires dthat dthe dfirst dday’s ddosage dbe dtwice dthose
